EXOZYMES INC. (EXOZ) Current Ratio
- Current ratio · latest quarter: Value 3.81×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 3.81× | Current assets / current liabilities. $6.17M ÷ $1.62M ≈ 3.81× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 6.17M USD | Assets, Current |
| Current obligations | 1.62M USD | Liabilities, Current |
| Cash and equivalents | 5.65M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 1.27M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.17M | $1.62M | $5.65M | (m) | (m) | (m) | $1.27M | (m) | 3.81× |
| 2026-03-31 | $2.09M | $1.58M | $1.44M | (m) | (m) | (m) | $1.23M | (m) | 1.32× |
| 2025-12-31 | $3.94M | $1.57M | $3.04M | (m) | (m) | (m) | $1.24M | (m) | 2.51× |
| 2025-09-30 | $5.61M | $1.24M | $5.10M | (m) | (m) | (m) | $904.35K | (m) | 4.53× |
| 2025-06-30 | $7.53M | $1.22M | $6.99M | (m) | (m) | (m) | $930.63K | (m) | 6.19× |
| 2025-03-31 | $9.42M | $1.44M | $8.51M | (m) | (m) | (m) | $1.07M | (m) | 6.52× |
| 2024-12-31 | $10.82M | $1.33M | $9.72M | (m) | (m) | (m) | $924.25K | (m) | 8.12× |
| 2024-09-30 | $1.42M | $5.80M | $233.94K | (m) | (m) | (m) | $908.61K | (m) | 0.25× |
| 2023-12-31 | $1.21M | $2.42M | $66.53K | (m) | (m) | (m) | $702.91K | (m) | 0.50× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |